Claims for Patent: 7,674,479

Summary for Patent: 7,674,479

Title:	Sustained-release bupropion and bupropion/mecamylamine tablets
Abstract:	Sustained-release bupropion hydrochloride pharmaceutical tablets and combination sustained-release bupropion hydrochloride/mecamylamine hydrochloride pharmaceutical tablets are obtained by granulating the bupropion hydrochloride with a hydroxyalkylcelluose, and blending the resulting granules within an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which then is coated, with a means to provide delayed release, such as with an enteric coating composition. The mecamylamine hydrochloride can be contained in a second granule comprising a hydroxyalkylcellulose.
Inventor(s):	Zerbe; Horst G. (Hudson, CA), Paiement; Nadine (Montreal, CA)
Assignee:	Intelgenx Corp. (St. Laurent, CA)
Application Number:	11/828,287
Patent Claims:	1. A sustained release pharmaceutical tablet comprising: sustained release granules consisting essentially of bupropion hydrochloride admixed with a hydroxyalkylcellulose; and an extragranular phase comprising a particulate material that provides a sustained release matrix; said particulate material is selected from the group consisting of polyvinylacetate, blends of polyvinylacetate and polyvinylpyrrolidone, a vinylpyrrolidone copolymer and polyethylene oxide, the granules being distributed within the extragranular phase. 2. The tablet of claim 1 further comprising sustained release mecamylamine hydrochloride granules. 3. The tablet of claim 1, wherein said extragranular phase further comprises mecamylamine hydrochloride. 4. The tablet of claim 1, wherein said hydroxyalkylcellulose is hydroxypropylcellulose. 5. The tablet of claim 1, further comprising an enteric coating. 6. A sustained release pharmaceutical tablet comprising: an uncoated sustained release granular phase comprising bupropion hydrochloride admixed with a hydroxyalkylcellulose; and an extragranular phase comprising a particulate material that provides a sustained release matrix; said particulate material is selected from the group consisting of polyvinylacetate, blends of polyvinylacetate and polyvinylpyrrolidone, a vinylpyrrolidone copolymer and polyethylene oxide, the uncoated granular phase being distributed within the extragranular phase. 7. The tablet of claim 6, further comprising sustained release mecamylamine hydrochloride granules. 8. The tablet of claim 6, wherein said extragranular phase further comprises mecamylamine hydrochloride. 9. The tablet of claim 6, wherein said hydroxyalkylcellulose is hydroxypropylcellulose. 10. The tablet of claim 6, further comprising an enteric coating.